Standigm Appoints Younsung Choo as CEO to Lead AI Drug Discovery and Development

Standigm, a South Korean company that specializes in artificial intelligence (AI) technology for drug discovery and development, has announced that Younsung Choo has been appointed as the new Chief Executive Officer (CEO). As the company’s new CEO, Choo will lead Standigm’s strategy, planning, research and development (R&D), and business development.

 

A Long-Time Advisor Takes the Helm

 

Choo is not a stranger to Standigm, having served as an advisor to the company since 2018. He brings to the role over 20 years of experience in the pharmaceutical industry, having held various positions at LG Life Sciences, including Head of R&D, Director of Global Business, and Director of Pharmaceutical Business. Choo was the project leader for Korea’s first U.S. Food and Drug Administration (FDA) new drug approval, Factive, and oversaw the development and approval of other successful drugs, including the first Korean biosimilar drug approved in the EU and USA, Human Growth Hormone (Valtropin).

 

Exciting Innovations in Drug Development and Discovery

 

In his new role, Choo’s focus will be on guiding Standigm through a challenging economic climate, with a particular emphasis on promising drug discovery and repurposing innovations, and diverse drug discovery projects. Standigm has spent several years developing its AI drug discovery platform based on in-house and external collaboration projects and is now ready to showcase its capabilities under Choo’s leadership.

 

Choo’s Natural and Exciting Next Step

 

Choo commented on his new role as CEO, saying, “Taking on the role of CEO feels like a natural and exciting next step for me. Standigm continues to grow and has already realized exciting innovations in drug development and discovery. The next phase of our company growth will be the biggest yet, as we continue to tackle the most important pharmaceutical challenges.”

 

Expanding the AI Drug Discovery Platform

 

According to Carl Foster, Standigm’s chief business officer, “In this changing economy, we are constantly expected to focus on shorter-term achievement to validate promising technologies. Under his leadership, Standigm will continue to expand its AI drug discovery platform so that we can identify new lead compounds and drug candidates and in-licensable pharmaceutical assets.”

 

Standigm’s AI drug discovery platform uses machine learning algorithms and data analysis to accelerate the drug discovery process. The platform allows scientists to identify new drug targets and optimize existing drug candidates faster and more efficiently than traditional methods.

 

Looking Ahead to a Bright Future

 

Standigm’s appointment of Younsung Choo as CEO is a significant move in the pharmaceutical industry, as the company continues to position itself as a leading player in the field of AI drug discovery and development. With Choo’s extensive experience and leadership, Standigm is poised to make significant strides in developing new drugs to address unmet medical needs and improve patient outcomes.

 

As the pharmaceutical industry continues to evolve, Standigm’s AI drug discovery platform will become increasingly critical in identifying new drug targets and optimizing existing drug candidates. With Younsung Choo at the helm, Standigm is well-positioned to lead the charge in revolutionizing the drug discovery process and developing life-saving therapies for patients around the world.

Conclusion

In conclusion, Younsung Choo’s appointment as CEO of Standigm is a significant development in the pharmaceutical industry. Choo’s experience and leadership will be instrumental in guiding Standigm through a challenging economic climate and developing innovative drugs to address unmet medical needs. With its AI drug discovery platform, Standigm is poised to make significant strides in revolutionizing the drug discovery process and improving patient outcomes.